Evaluation of Unexplained Weight Gain

1. Confirming That BMI Rise Represents True Adiposity

• Assess for conditions that can increase body weight without added fat, including peripheral edema or fluid retention, increased spirometric volume in athletes, pregnancy, palpable large tumors or organomegaly, sarcopenia with fluid accumulation in older adults, and lipodystrophy with abnormal fat distribution. [American College of Endocrinology & American Association of Clinical Endocrinologists] 1, 2, 3
• In athletes, a high spirometric volume can falsely elevate BMI despite normal adiposity. [American College of Endocrinology & American Association of Clinical Endocrinologists] 1
• Always exclude pregnancy in women of reproductive age when evaluating weight gain. [American College of Endocrinology & American Association of Clinical Endocrinologists] 1
• Palpable masses suggesting large tumors or organomegaly should be investigated as alternative explanations for weight increase. [American College of Endocrinology & American Association of Clinical Endocrinologists] 2
• Sarcopenia combined with fluid overload, particularly in elderly patients, can mimic obesity. [American College of Endocrinology & American Association of Clinical Endocrinologists] 2
• Lipodystrophy (abnormal fat distribution patterns) must be considered when BMI is high but peripheral fat is deficient. [American College of Endocrinology & American Association of Clinical Endocrinologists] 2
• When clinical assessment is inconclusive, employ body‑composition tools such as bioelectrical impedance analysis, air‑displacement plethysmography, or dual‑energy X‑ray absorptiometry (DEXA). [American College of Endocrinology & American Association of Clinical Endocrinologists] 1, 2

2. Secondary Hormonal Causes

Hypothyroidism

• Measure serum TSH in every patient with unexplained weight gain to screen for hypothyroidism. [American College of Endocrinology & American Association of Clinical Endocrinologists] 1, 2

Cushing Syndrome (Hypercortisolism)

• Typical clinical features include central adiposity, facial plethora, violaceous striae, proximal muscle weakness, hirsutism, and menstrual irregularities (amenorrhea). [American College of Endocrinology & American Association of Clinical Endocrinologists] 2

Polycystic Ovary Syndrome (PCOS)

• Laboratory evaluation should include an elevated LH:FSH ratio, increased circulating androgens, and reduced sex‑hormone‑binding globulin (SHBG). [American College of Endocrinology & American Association of Clinical Endocrinologists] 2

3. Iatrogenic (Medication‑Induced) Weight Gain

• High‑risk medications for weight gain include atypical antipsychotics (e.g., olanzapine, clozapine, quetiapine), certain antidepressants (tricyclics, mirtazapine, paroxetine), systemic corticosteroids, and insulin or sulfonylurea agents used for diabetes management. [American College of Endocrinology & American Association of Clinical Endocrinologists] 2
• Recommended action: discontinue the offending drug when feasible or substitute with a weight‑neutral alternative, and arrange follow‑up to confirm resolution of the weight gain. [American College of Endocrinology & American Association of Clinical Endocrinologists] 2

4. Genetic and Syndromic Obesity

• Alarm features suggesting a monogenic or syndromic form of obesity include onset before age 5, dysmorphic facial or skeletal features, behavioral hyperphagia, and a strong family history of early‑onset obesity. [American College of Endocrinology & American Association of Clinical Endocrinologists] 2
• When these clinical clues are present, genetic testing of the patient (and possibly relatives) is indicated to identify specific mutations (e.g., leptin deficiency, MC4R variants). [American College of Endocrinology & American Association of Clinical Endocrinologists] 2

5. Ancillary Laboratory Screening

• In patients where an eating‑disorder is suspected, obtain a complete blood count and assess serum electrolytes; hypokalemia may be a marker of purging behavior. [American College of Endocrinology & American Association of Clinical Endocrinologists] 1

Laboratory Evaluation for Increased Appetite

Initial Metabolic and Endocrine Screening

• Order a comprehensive metabolic panel, fasting glucose, hemoglobin A1C, thyroid‑stimulating hormone, and a morning cortisol + ACTH measurement to screen for the most common endocrine causes of increased appetite (e.g., Cushing syndrome, hyperthyroidism, diabetes mellitus). The American College of Endocrinology recommends this panel. 4
• Include a complete metabolic panel (electrolytes, liver enzymes, renal function) for every patient with increased appetite to detect metabolic derangements and potential complications. 5
• Measure fasting glucose and hemoglobin A1C to identify diabetes mellitus or pre‑diabetes, conditions that can paradoxically increase appetite despite hyperglycemia. 6

Cushing Syndrome Evaluation

• Perform late‑night salivary cortisol on two separate evenings; the test shows 92‑100 % sensitivity and 93‑100 % specificity for Cushing syndrome. 4
• If salivary cortisol is elevated or equivocal, obtain a 24‑hour urinary free cortisol measurement. 4
• When initial screening is abnormal, obtain a morning plasma ACTH together with serum cortisol to differentiate ACTH‑dependent from ACTH‑independent hypercortisolism. The National Comprehensive Cancer Network recommends this approach. 7
• An alternative screening test is the 1‑mg overnight dexamethasone suppression test; a post‑dexamethasone serum cortisol > 5 µg/dL indicates Cushing syndrome. 8

Pituitary Adenoma and Insulinoma Assessment

• Measure serum prolactin and insulin‑like growth factor‑1 to screen for pituitary adenomas that may cause dysregulated appetite. The National Comprehensive Cancer Network recommends this screening. 9
• In patients with documented hypoglycemic episodes, obtain fasting insulin, proinsulin, and C‑peptide; values exceeding established thresholds (insulin > 3‑6 µIU/mL, C‑peptide ≥ 0.6 ng/mL, proinsulin ≥ 5 pmol/L) suggest an insulinoma. 9

Neuroendocrine Tumor Screening (Gastrinoma, Glucagonoma, VIPoma)

• Order a fasting serum gastrin level when a gastrinoma is suspected (e.g., refractory peptic ulcer disease). 9
• Obtain serum glucagon in patients with necrolytic erythematous rash, unexplained weight loss, or recent‑onset diabetes to evaluate for glucagonoma. 9
• Measure serum vasoactive intestinal peptide (VIP) and electrolytes when a VIPoma is considered (characteristic watery diarrhea). 9

Primary Aldosteronism Evaluation

• Determine plasma aldosterone concentration (PAC) and plasma renin activity (PRA); a PAC : PRA ratio > 30 is suggestive of primary aldosteronism. The National Comprehensive Cancer Network endorses this ratio. 7
• Check serum electrolytes to document hypokalemia and hypernatremia that often accompany primary aldosteronism. 7

Laboratory Assessment in Suspected Eating Disorders

• Perform a complete blood count to detect anemia, leukopenia, or other hematologic abnormalities that may accompany binge‑eating or bulimia. The American Psychiatric Association recommends this evaluation. 5
• Assess electrolytes to identify hypokalemia resulting from purging behaviors. 5
• Obtain liver function tests because transaminases can be modestly elevated in patients with chronic vomiting or laxative abuse. 5

Clinical Management Pitfalls (Safety Recommendations)

• Do not delay treatment of suspected acute adrenal insufficiency or severe hypoglycemia while awaiting laboratory results; immediate therapy is essential. 10
• Avoid using octreotide or lanreotide in patients with insulinoma unless somatostatin‑receptor positivity is confirmed, as these agents can worsen hypoglycemia by suppressing counter‑regulatory hormones. 9
• Recognize that normal cortisol levels may be inappropriately low during acute illness; paired ACTH measurement is required for accurate interpretation. 10
• Review current medications (e.g., antipsychotics, antidepressants, corticosteroids, insulin, sulfonylureas) that can increase appetite before initiating extensive endocrine testing. The American College of Endocrinology advises this medication review. 11